Health‐related quality of life among transthyretin amyloid cardiomyopathy patients

AIMS Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health-related quality of life (HRQoL) in ATTR CM patients. METHODS AND RESULTS The Nordic PROACT study was a cross-sectional non-interventional study conducted in 12 cardiology hospital clinics across Norway, Sweden, Finland and Denmark. Men and women aged ≥18 years diagnosed with symptomatic ATTR CM were included. The investigator provided information on medical history, biomarkers, current treatment, co-morbidities and disease severity according to the New York Heart Association (NYHA) class and the National Amyloidosis Centre (NAC) staging. Patients completed the HRQoL questionnaires in the form of the Kansas City Cardiomyopathy Questionnaire (KCCQ), the EQ-5D-5L index with Visual Analog Scale (VAS), and the Major Depression Inventory (MDI). A total of 169 patients (mean ± SD age 77.7 ± 6.2 years) were included. Ninety-two per cent were men. Seventy-six per cent had wildtype ATTR CM (ATTRwt CM) and 15% had a hereditary form of ATTR CM (ATTRv CM) while 9% were genetically unclassified. Most patients were in NYHA class II (54%) and NAC stage 1 (53%). Participation in randomized clinical trials (RCT) was noted in 58% of the patients. The 169 ATTR CM patients had a mean ± SD KCCQ score of 64.3 ± 23.1 for total symptom score, 64.8 ± 20.9 for overall summary score (OSS) and 65.1 ± 21.5 for clinical summary score. The EQ-5D-5L total utility score was 0.8 ± 0.2 and the EQ-5D-5L VAS score was 62.9 ± 20.6. The vast majority (89%) did not report any signs of depression. Patients with ATTRv CM had a higher KCCQ OSS as compared with ATTRwt CM, while EQ-5D-5L utility score, EQ-5D-5L VAS and MDI were similar. Non-RCT participants had a poorer HRQoL as compared with RCT participants as reflected in lower KCCQ OSS and EQ-5D-5L VAS scores and a higher MDI score. Patients with higher NYHA classes and NAC disease stages had a poorer HRQoL as demonstrated by lower KCCQ and EQ-5D-5L scores and higher MDI scores. Correlation between KCCQ, EQ-5D-5L and MDI and the covariate NYHA class remained significant (P < 0.05) after adjusting for multiple testing. CONCLUSIONS KCCQ scores were lower than previously reported for patients with other heart diseases of non-ATTR CM origin. The HRQoL measures correlated well to NYHA class and NAC disease stage. The prevalence of depression appeared to be low.

[1]  J. Smith,et al.  Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries , 2022, ESC heart failure.

[2]  K. Bay,et al.  Suspicion, screening, and diagnosis of wild‐type transthyretin amyloid cardiomyopathy: a systematic literature review , 2022, ESC heart failure.

[3]  V. Planté-Bordeneuve,et al.  Amyloidosis from the patient perspective: the French daily impact of amyloidosis study , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[4]  J. Fine,et al.  Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial , 2021, Journal of medical economics.

[5]  T. B. Rasmussen,et al.  Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2021, Journal of the American College of Cardiology.

[6]  A. Garay,et al.  Quality of life and disease experience in patients with heart failure with reduced ejection fraction in Spain: a mixed-methods study , 2021, BMJ Open.

[7]  C. Gudex,et al.  Danish population health measured by the EQ-5D-5L , 2021, Scandinavian journal of public health.

[8]  M. Maurer,et al.  Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. , 2021, Future cardiology.

[9]  U. Gerdtham,et al.  Inequality and heterogeneity in health-related quality of life: findings based on a large sample of cross-sectional EQ-5D-5L data from the Swedish general population , 2021, Quality of Life Research.

[10]  J. Smith,et al.  Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden , 2021, Open Heart.

[11]  S. Hohnloser,et al.  Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study , 2021, European heart journal. Quality of care & clinical outcomes.

[12]  R. Kornowski,et al.  Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy , 2021, European journal of heart failure.

[13]  A. Masri,et al.  Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review , 2021, Cardiology and Therapy.

[14]  A. Garratt,et al.  Norwegian population norms for the EQ-5D-5L: results from a general population survey , 2021, Quality of Life Research.

[15]  E. Schulze-Bahr,et al.  Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK) , 2021, Clinical Research in Cardiology.

[16]  M. Maurer,et al.  Impact of Tafamidis on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy (From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). , 2020, The American journal of cardiology.

[17]  B. Popescu,et al.  Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire , 2020, Health and Quality of Life Outcomes.

[18]  C. O'connor,et al.  Depression and heart failure: the lonely comorbidity , 2020, European journal of heart failure.

[19]  S. Ajroud‐Driss,et al.  Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis , 2020, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[20]  R. Falk,et al.  Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) , 2020, Cardiovascular Drugs and Therapy.

[21]  M. Maurer,et al.  Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. , 2020, Annual review of medicine.

[22]  H. Vase,et al.  Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. , 2020, International journal of cardiology.

[23]  S. Solomon,et al.  Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. , 2019, JACC. Heart failure.

[24]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[25]  C. Rapezzi,et al.  Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2019, European heart journal.

[26]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[27]  W. Lenderking,et al.  Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers , 2018, Neurology and Therapy.

[28]  M. Halushka,et al.  Seven factors predict a delayed diagnosis of cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[29]  P. Bech,et al.  The criterion validity of the web-based Major Depression Inventory when used on clinical suspicion of depression in primary care , 2017, Clinical epidemiology.

[30]  K. Juel,et al.  DenHeart: Differences in physical and mental health across cardiac diagnoses at hospital discharge. , 2017, Journal of psychosomatic research.

[31]  S. Cay,et al.  Heart Failure Functional Class Associated with Depression Severity But Not Anxiety Severity. , 2016, Acta Cardiologica Sinica.

[32]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[33]  M. Maurer,et al.  THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis , 2013, Current medical research and opinion.

[34]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[35]  C. O'connor,et al.  Relation of depression to severity of illness in heart failure (from Heart Failure And a Controlled Trial Investigating Outcomes of Exercise Training [HF-ACTION]). , 2009, The American journal of cardiology.

[36]  P. Bech,et al.  Applicability and validity of the Major Depression Inventory in patients with Parkinson's disease , 1998 .

[37]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.